1. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials;Aday;Psychopharmacology,2022
2. Biogen (2021) Sage therapeutics and biogen announce positive pivotal phase 3 results for zuranolone, an investigational two-week, once-daily therapeutic being evaluated for major depressive disorder. Available at: https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-positive-pivotal-phase-3.
3. Biogen (2022) Sage therapeutics and biogen announce that the phase 3 SKYLARK study of zuranolone in postpartum depression met its primary and all key secondary endpoints. Available at: https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-phase-3-skylark-study.
4. Trial of psilocybin versus Escitalopram for depression;Carhart-Harris;N Engl J Med,2021
5. Compass Pathways PLC (2021) COMP360 psilocybin therapy for treatment-resistant depression- Phase IIb topline data. https://compasspathways.com/wp-content/uploads/2021/11/COMP001_-_topline_data.pdf.